

Curriculum Vitae

Sreenivasa R. Chinni, Ph.D.

Office Address: 9245 Scott Hall
Department of Urology
540 East Canfield Ave
Detroit, MI 48201

Office Telephone: 313 577 1833

Office Fax: 313 577 0057

EDUCATION:

Baccalaureate:

B. Sc. (Major: Zoology) Sri Venkateswara University, Tirupati, India. April 1983.

Graduate:

M.Sc. (Zoology) Sri Venkateswara University, Tirupati, India. May 1986.

M.Phil.(Animal Physiology) Sri Venkateswara University, Tirupati, India. August 1988.

Ph.D. (Biochemistry) University of Louisville, Louisville, KY. May 1998.

TRAINING:

Graduate Teaching Assistant, Department of Biochemistry,
University of Louisville. 1992

Graduate Research Assistant, Department of Biochemistry,
University of Louisville. 1993

Post-Doctoral Fellow, Department of Physiology, Wayne State University. 1997

Post-Doctoral Fellow, Department of Pathology, Wayne State University. 1999

FACULTY APPOINTMENTS:

Assistant Professor (Research), Departments of Urology and Pathology,
Wayne State University. 2001

Assistant Professor (Research Educator Track), Departments of Urology
and Pathology, and Barbara Ann Karmanos Cancer Institute,
Wayne State University. 2006-2012

Member of Proteases and Cancer program, Karmanos Cancer Institute. 2004-2012

Member of Tumor and Microenvironment program, Karmanos Cancer

Institute	2012-Present
Member of Cancer Biology Graduate Program, Wayne State University.	2010-Present
Associate Professor (Tenure), Departments of Urology and Pathology, Wayne State University.	2012- Present

MAJOR PROFESSIONAL SOCIETIES:

Associate Member, American Association of Cancer Research.	1994-2003
Member, American Association of Cancer Research.	2003-Present
Member, International Metastasis Research Society.	2002-Present

HONORS/AWARDS:

Outstanding Senior Zoology Award.	1983
Junior Research Fellowship, Department of Science and Technology, Govt. of India.	1986
Hamburger's Fellowship, Department of Biochemistry, University of Louisville.	1991
Deans Distinguished Post Doctoral Fellow, Wayne State University School of Medicine	1999
American Institute of Cancer Research Fellow.	2000

SCHOLARLY SERVICE

Grant Review Committees:

National/International:

Department of Defense Prostate Cancer, Pathobiology study section	2008
Department of Defense Prostate Cancer, pre-Pathobiology study section.	2009
Department of Defense Breast Cancer, Cell Biology study section.	2010
Department of Defense Prostate Cancer, Cell Biology study section.	2011
Department of Defense Prostate Cancer, pre-Pathobiology stud section and Cell Biology study section.	2012
Department of Defense Prostate Cancer, pre-Pathobiology and post-doctoral grant study section	2013
Department of Defense, Prostate Cancer Research Program, PBY study section.	2015
Center for Scientific Review, National Institutes of Health, F09B fellowship applications in Oncological Sciences.	2015
Swiss National Science Foundation, Division of Biology and Medicine, Grant application.	2015

Regional:

Henry Ford Health Systems. Internal Grant Program study section.	2007, 2014,2015
American Cancer Society, Institutional Review Grant, Karmanos Cancer Institute.	2011-2014
Karmanos Cancer Insitute, Strategic Research Initiative Grant RFA.	2015

Service for Peer-Reviewed Journals:

Editorial board: Journal of Cancer Science and Therapy. 2010-Present
Manage review of two articles for year.

Reviewed manuscripts for following journals*: Nature, Biochemical J, Cancer Research, Journal of Biological Chemistry, Oncogene, Cancer Letters, Biochemistry and Biophysics Acta., Molecular Cancer Therapeutics, Breast Cancer Research and Treatment, Molecular Cancer, Journal of Cancer Science and Therapy, Urologic Oncology, Asian Journal of Andrology, PLoS ONE and Endocrine related cancers.

* A total of 5-7 manuscripts were reviewed per year starting from 2006-Present

Wayne State University/Department service:

Pathology Department's core equipment maintenance committee. 2009-Present
Interviewer, Faculty candidate recruitment at Pathology Department, in the areas of Cancer Research and Diabetes and Metabolic disorders. 2009-2012
Cancer Biology Department's thesis committee. 2010-Present
Member, Karmanos Cancer Institute, American Cancer Society
Institutional Research Grant review committee. 2011-Present
Member, Karmanos Cancer Institute's Scientific Leadership Council. 2012-2015
Member, Faculty annual evaluation committee, Department of Urology 2013-Present
Member, Institutional Biosafety committee 2013-Present
Member, Faculty recruitment committee, Tumor and Microenvironment program, Karmanos Cancer Institute 2013-Present
Member, P and T committee, CMMG/Dermatology Department 2015

Academic service:

Judge for the posters at the 6th Annual Research Symposium of Henry Ford Health System. 2009
Judge for the posters at 13th annual Graduate Students Research Day at Wayne State University. 2009
Judge for the posters at 9th symposium of Michigan Prostate Research Colloquium on Prostate Tumor Microenvironment and Metastasis, Wayne State University. 2009
Judge for the posters at the Annual Research Symposium of Henry Ford Health System. 2010-2013
Judge of the posters at Annual Graduate Students Research Day at Wayne State University. 2010-2015
Judge of the posters at Cancer Biology Department's Graduate students Research Day. 2011-2015

TEACHING

Courses taught at Wayne State University:

Graduate Courses

PTH8000

Role: Course co-director and Instructor, responsible for class room instruction for five classes. Two new lectures were developed on "Organ specific metastasis" and "Experimental metastasis". 2007-2009

PTH7090

Role: Instructor, responsible for class room instruction of two classes. One new lecture was developed on "FGF signaling and Angiogenesis in Cancer". 2009-2013

MDR7110

Role: Faculty mentor, responsible for precepting student in oral presentation on Prostate Cancer. 2008

CB7460

Role: Instructor, responsible for class room instruction of four classes. Two new lectures were developed on "Androgen signaling and Prostate Cancer" and "GPCR signaling and Metastasis." 2010-Present

CB7210

Role: Course Director. This is a team taught flagship course of Cancer Biology. Responsible for revising course contents, developing syllabus, coordinate a team of faculty lectures, organize and conduct three exams. 2011

CB7210

Role: Instructor, responsible for class room instruction of one lecture on Metastasis. 2011-Present

CB7710 Cancer biology graduate student rotations.

Role: Instructor, responsible for laboratory research project training. 2010-Present

CB7996 Cancer biology graduate research.

Role: Mentor, responsible for thesis project progress. 2011-Present

Mentorship:

Undergraduate Students:

Douglas Smith, Undergraduate student, University of Michigan, Ann Arbor, MI. Research project on "Phosphatidylinositol 4-kinase Type III α (PI4KA) expression in prostate cancer cells." 2015 Summer

Ussama Khan, Undergraduate student, Wayne State University. Research project on bioinformatics analysis of gene expression profiles in public databases. 2014-Present

Evan Bylett, Undergraduate student, Michigan State University, Lansing, MI. Research project on "Cloning of ERG factor in lentiviral vectors." 2014 Summer

Sukhdeep Singh B, Undergraduate student, Wayne State University. Research project

on “Plerixafor inhibition of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.” 2013 Summer

Maria Agostini, Undergraduate student, University of Michigan, Ann Arbor, MI. Research project on “Establishing a stable wild type ERG-V5 expressing PC-3 cells.” 2012 Summer

Nina Bihani, Undergraduate MedStart Student, Wayne State University. Research project on “Expression of ERG transcription factors in prostate cancer”. 2011- Present

Petersen Decker, Undergraduate student, University of Michigan. Research project on “Cross talk between Akt and MAPK pathways in prostate cancer cells”. 2011 Summer

Ashley Ann Joseph, Undergraduate MedStart Student, Wayne State University. Research project on “Cloning of ERG transcription factors”. 2010 – 2011

Meggan Shell, Undergraduate Student, Michigan State University. Research project on “Development of in vitro translation system for ERG factor expression”. 2010 Summer

Jason St. John, BMS student, Wayne State University. Research project on “Mutant ERG transcription factor cloning”. 2009 Summer

Pridvi Kandagatla MedStart student, Wayne State University. Research project on “Targeting CXCR4 function with peptide inhibitor for prostate cancer metastasis” 2009 Summer

Anthony Kropinski, Undergraduate Student, Wayne State University. Research project on “Preparing ERG factor expression constructs”. 2008 – 2010

Pridvi Kandagatla, Undergraduate Student, MedStart Program, Wayne State University. Research project on “Targeting CXCR4 function with peptide inhibitor for prostate cancer metastasis”. 2006-2010

Sheetal Kerkar. Kalamazoo College, MI. Undergraduate student. Summer research project on “Characterizing gene expression profiles in prostate cancer”. 2001 Summer

John C. Gohde. Indiana University. Undergraduate student. Summer research project on “Chemopreventive effect of Indole 3 Carbinol on prostate cancer cells”. 2000 Summer

Graduate Students:

Rotations:

Katelyn Powell, Graduate Student, Cancer Biology, Wayne State University. Rotation project on “ERG transcription factor and Prostate cancer”. 2011 Winter

Aaron Burr, Graduate Student, Cancer Biology, Wayne State University. Rotation project on “Characterization of CXCR4 promoter luciferase reporter constructs” 2010 Fall

Thesis Research:

Katelyn Powell, Graduate Student, Cancer Biology Department, Wayne State University.
2011-Present

Medical Student

Joon Choi, Second year medical student, Wayne State University. 2014

Post-doctoral fellows

Diego Sbrissa, Ph.D., Research Associate, Department of Urology, Wayne State University. 2014-Present

Mary Conley-LaComb, Ph.D., Post Doctoral Research Associate, Department of Urology, Wayne State University. 2011- 2014

Rajareddy Singareddy, Ph. D., Post Doctoral Research Associate, Department of Urology, Wayne State University. 2009 – 2012

Essays/Theses/Dissertations directed:

Ph.D thesis advisor for Ms. Katelyn Powell 2011-2014

Member of Ph.D thesis committee of Ms. Sara M. Schmitt (Advisor: Dr. Ping Dou), Cancer Biology Program. Thesis project on “Molecular Studies on Zinc and Zinc compounds for treatment of prostate cancer”. 2011-2014

Mentor of essay committee of Mr. Jason St. John, BMS student. Essay title “*Ets* Transcription Factor Expression in Prostate Tumor Cells and its Clinical and Biological Significance in Prostate Cancer Progression” 2010

Mentor of Undergraduate Research thesis of Mr. Pridvi Kandagatla, Medstart student. Thesis title” CXCR4 Antagonist, CTCE-9908 Inhibits Prostate Tumor Angiogenesis”. 2010

Member of essay committee of Mr. Irish Jonathan (Advisor: Dr. Shijie Sheng), BMS student. Thesis title “The RANK/RANKL/OPG Axis is a Potential Drug Target for the Treatment of Prostate Cancer Metastasis in Bone”. 2008

Research Personnel Training:

Louie Semaan, BS., Research Assistant, Department of Urology, Wayne State University. 2011– Present

Li Yanfeng, MS., Research Assistant, Department of Urology, Wayne State University School of Medicine 2012-2015

Jason St. John, Research Assistant, Wayne State University. 2009 – 2011

Anthony Kropinski, Research Assistant, Wayne State University.	2008-2010
Becky Cai, Research Assistant, Wayne State University.	2006-2008
Hamilto Yamamoto, Research Assistant, Wayne State University.	2006-2007
Trindade Filho JC, Research Assistant, Wayne State University.	2005-2006
Sivasakthy Sivalogan, Research Assistant, Wayne State University.	2002-2006

GRANT, CONTRACTS, AND OTHER FUNDING:

Active Grants and Contracts:

Agency: National Cancer Institute, National Institutes of Health – R01
 PI: Sreenivasa R. Chinni, 40 % effort.
 Title: Novel ERG regulation of CXCR4 in prostate cancer progression.
 Amount: \$1,018,745 direct costs.
 Period: July 2010 - April 2016 (No cost extension).

Agency: Department of Defense – Exploration and Hypothesis development grant.
 PI: Sreenivasa R. Chinni, 10 % effort.
 Title: Uncarboxylated ostocalcin and Gprc6a axis produce intratumoral androgens in castration resistant prostate cancer.
 Amount: \$75,000 direct costs.
 Period: February 2014 – March 2016 (No cost extension).

Agency: Department of Defense, Idea Award
 Co-Investigator: Sreenivasa R. Chinni, 3 % effort (PI: Dr. Yang)
 Title: Inhibition of histone demethylase GASC1: a novel strategy to treat castration-resistant prostate cancer.
 Amount: \$335, 232 direct costs.
 Period: June 2013 – May 2016.

Agency: Karmanos Cancer Institute
 Co-Investigator: Sreenivasa R. Chinni, (PI: Dr. Ulka Vaishampayan)
 Title: Randomized Phase II screening trial of enzalutamide/MDV-3100 and LHRH analogue vs combined androgen deprivation (LHRH analogue + bicalutamide) in metastatic hormone sensitive prostate cancer.
 Amount: \$89,000
 Period: July 2014 – September 2016

Agency: Astellas Scientific and Medical Affairs Inc.,
 Investigator: Sreenivasa R. Chinni,
 Title: Efficacy of enzalutamide inTMPRSS2-ERG fusions in castrate resistant prostate cancer.
 Amount: \$50,490
 Period: March 2015 – February 2016

Agency: Wayne State University School of Medicine
Mentor: Sreenivasa R. Chinni (PI: Joon Choi, Medical Student)
Title: TMPRSS2-ERG regulation of androgen synthesis
Amount: \$2,500 for student stipend and \$1,000 for Mentor
Period: June 2014 – August 2014

Pending National/International Grants and Contracts:

Agency: Department of Defense – Idea Award
PI: Sreenivasa R. Chinni, 15 % effort.
Title: PI4KIIIa Cross-Talk with Chemokine Signaling in Prostate Cancer Bone Metastasis.
Amount: \$375,000 direct costs + 201,873 indirect costs.
Period: April 2016 – March 2019.

Agency: Sinai Staff Foundation
PI: Sreenivasa R. Chinni.
Title: Intratumoral androgen production by osteocalcin/G α 6a in prostate cancer bone metastasis.
Amount: \$75,000 direct costs.
Period: 3 years.

Agency: Bayer pharmaceuticals
PI: Sreenivasa R. Chinni, 8 % effort.
Title: Testing the efficacy of ODM-201 in TMPRSS-ERG fusions in castrate resistant prostate cancer using intra-tibial bone metastasis mode.
Amount: \$87,662 direct costs + \$47,337 indirect costs.
Period: 1 year.

Previously funded Grants and Contracts:

Agency: Department of Defense – Idea Award
PI: Sreenivasa R. Chinni, 30 % effort.
Title: The role of ERG and CXCR4 in prostate cancer metastasis.
Amount: \$371,251 direct costs.
Period: April 2009 – March 2013.

Agency: Fund for Cancer Research
PI: Sreenivasa R. Chinni, 20 % effort
Title: The Role of CXCR4 in Prostate Cancer Bone Metastasis.
Amount: \$ 75,000 direct costs.
Period: May 2008 – April 2012.

Agency: MedStart summer research program, Wayne State University
Role: Faculty sponsor and mentor for Mr. Pridvi Kandagla

Title: Cloning CXCR4 promoter deletion constructs.
Amount: \$ 2,500.
Period: Summer 2008

Agency: Fund for Cancer Research
PI: Sreenivasa R. Chinni, 20 % effort.
Title: Novel Role of CXCR4 in Prostate Cancer Bone Metastasis.
Amount: \$ 75,000 direct costs.
Period: May 2007 – April 2008.

Agency: Department of Defense
PI: Sreenivasa R. Chinni, 50 % effort.
Title: The Role of SDF-1 α /CXCR4/MMP in PC Bone Metastasis.
Amount: \$335,165 direct costs.
Period: Mar 2003-Mar 2006.

Agency: American Institute of Cancer Research
PI: Sreenivasa R. Chinni, 35% effort.
Title: Molecular analysis of Indole-3-Carbinol signaling events in prostate cancer cells.
Amount: \$54,000 direct costs
Period: Jan 2001-Dec 2002.

PUBLICATIONS:

1. Neeraja, P., **Chinni, SR.**, and Santhi, K. Response of fish, *Oreochromis mossambicus* to ambient ammonium sulphate stress. *Journal of Inland Fisheries Society of India*. 19 (2); 32-36, 1987.
2. **Chinni, SR.**, and Neeraja, P. Transamination pattern and protein levels in selected tissue of fish, *Tilapia mossambica* on chronic ammonia stress. *Environment & Ecology*. 7 (4); 915-917, 1989.
3. **Chinni, SR.**, and Neeraja, P. Effect of chronic ammonia stress on some aspects of protein metabolism of fish, *Tilapia mossambica*. *Indian Journal of Comparative Animal Physiology*. 8 (1); 88-91, 1990.
4. **Chinni, SR.**, Falchatto, RA., Gercel-Taylor, C., Shabanowitz, J., Hunt, DF., Taylor, DD. Humoral immune response to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. *Clinical Cancer Research* 3: 1557-1564, 1997.
[Journal impact factor: 7.3; Cited: 23]
5. **Chinni, SR.**, Gercel-Taylor, G, Conner, GE and Taylor, DD. Cathepsin D core protein elicits immune response in ovarian cancer patients. *Cancer Immunology and Immunotherapeutics*. 46:48-54, 1998.
[Journal impact factor: 4.3; Cited: 17]

6. **Chinni, SR**, Brenz, M and Shisheva, A. Modulation of GDI protein membrane retention by the cellular redox state. *Experimental Cell Research*. 242:373-380, 1998. (Study design, implementation, data analysis and manuscript writing)
[Journal impact factor: 3.8; Cited: 7]
7. **Chinni, SR** and Shisheva, A. Arrest of endosome acidification by Bafilomycin A1 promotes GLUT4 translocation in 3T3-L1 adipocytes through insulin receptor independent mechanism. *Biochemical J*. 339(3):599-606, 1999.
[Journal impact factor: 5.0; Cited: 18]
8. Shisheva, A. **Chinni, SR** and DeMarco, C General role of GDP-dissociation inhibitor-2 in membrane release of Rab proteins: Modulations of its functional interactions by *in vitro* and *in vivo* structural modifications. *Biochemistry*. 38(36):11711-21, 1999.
[Journal impact factor: 3.2; Cited: 19]
9. Li, Y, **Chinni, SR** and Sarkar, FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. *International Journal of Oncology* 17(4):755-9, 2000.
[Journal impact factor: 2.6; Cited: 22]
10. Rahman KM, Aranha O, Glazyrin A, **Chinni SR** and Sarkar FH. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. *Oncogene*. 19(50):5764-71, 2000.
[Journal impact factor: 7.4; Cited: 50]
11. **Chinni SR**, Li Y, Upadhyay S, Koppolu PK and Sarkar, FH. Indole-3-Carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. *Oncogene*. 20(23):2927-36, 2001.
[Journal impact factor: 7.4; Cited: 131]
12. Upadyay, S., Neburi, M., **Chinni SR**, Alhasan S., Miller, F and Sarkar F. Differential effects of genistein on normal and malignant cells are mediated by p21^{WAF1}. *Clin. Can. Res*. 7(6):1782-9. 2001.
[Journal impact factor: 7.4; Cited: 42]
13. Glyzyrin. AL., **Chinni, SR**, Alhasan S, Adsay VN, Vaitkevicius VK and Sarkar FH. Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis. *Int. J. Oncol*. 20(1):201-5, 2002.
[Journal impact factor: 2.6; Cited: 6]
14. **Chinni, SR**. and Sarkar, FH. Akt inactivation is a key event in Indole-3-Carbinol (I3C) induced apoptosis of PC-3 cells. *Clin. Can. Res*. 8(4):1228-36, 2002.
[Journal impact factor: 7.4; Cited: 91]

15. **Chinni, SR**, Alhasan, SA, Multani AS, Pathak, S and Sarkar FH. Pleiotropic effects of genistein on MCF-7 breast cancer cells. *Int. J. Mol. Med.* 12(1):29-34, 2003.
[Journal impact factor: 1.8; Cited: 17]
16. Hussain, M., Sarkar, F.H., Djuic, Z., Pollak, M.N., Banerjee, M., Fontana, F., Eilender, D., Davis, J **Chinni, SR.**, Trivedi, C., Forman, J., Wood, D.P., and Kucuk. O. Soy isoflavones modulate serum PSA level in patients with prostate cancer. *Nutrition and Cancer* 47(2): 111-117, 2003.
[Journal impact factor: 2.6; Cited: 76]
17. Li Y, **Chinni SR** and Sarkar FH. Selective growth regulatory and pro-apoptotic effects of DIM are mediated by Akt and NF- κ B pathways in prostate cancer cells. *Frontiers in Biosciences.* 10: 236-243, 2005.
[Journal impact factor: 3.7; Cited: 31]
18. Dong Z, Bonfil, RD, **Chinni SR**, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Slone B, Sheng S, Fridman R and Cher ML. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. *American Journal of Pathology.* 166(4):1173-86, 2005.
[Journal impact factor: 5.7; Cited: 49]
19. ¹**Chinni SR**, Sivalogan S, Dong Z, Trindade Filho, JC, Deng X, Bonfil RD and Cher ML. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. *The Prostate.* 66(1):32-48, 2006. (¹Corresponding author).
[Journal impact factor: 3.4; Cited: 73]
20. Bonfil, R. D., Sabbota, A., Nabha, S., Dong, Z., Meng, H., Yamamoto H., **Chinni, SR.**, Bernardo, M. M., Lim, I. T., Chang, M., Filetti, L. C., Mobashery, S., Cher, M. L., Fridman, R. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. *International Journal of Cancer.* 118:2721-2726, 2006. [Data analysis and manuscript editing].
[Journal impact factor: 4.9; Cited: 31]
21. *Deng, X., Bhagat, S., Dong, Z., Mullins, C., **Chinni, S.R.**, Cher, M.L. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. *Eur. J. Cancer.* 42(18):3267-3273, 2007. (*Post-doctoral fellow of Dr. Cher trained in my lab in *in vitro* techniques). [Intellectual input, data analysis and manuscript writing for select sections].
[Journal impact factor: 4.9; Cited: 11]
22. [&]Yamamoto, H., Bonfil, R.D., Wiesner, C., Nabha, S., Dong, Z., Meng, H., Saliganan, A., Sabbota, A., **Chinni, S.R.**, Cher, M.L. Quantitative

assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging. *Prostate*. 67(1):107-114, 2007. (*&Research fellow of Dr. Cher trained in my lab on in vitro techniques*). [Intellectual input, data analysis and manuscript writing for select sections]. [Journal impact factor: 3.4; Cited: 2]

23. Bonfil, R. D., Dong, Z., Trindade Filho, J. C., Osenkowski, P., Nabha, S., **Chinni, S.R.**, Yamamoto, H., Sabbota, A., Vessella, R. L., Fridman, R., Cher, M. L. Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Promotes Tumor Growth and Bone Degradation in Prostate Cancer Bone Metastasis. *American Journal of Pathology*. 170(6):2100-11, 2007. [Intellectual input, data analysis and manuscript editing]. [Journal impact factor: 5.7; Cited: 21]
24. ¹**Chinni, S.R.**, *Dong Z, Hamilo Y, Bonfil RD and Cher ML. CXCL12/CXCR4 trans-activates HER2 in lipid rafts of PC cells and promotes *in vivo* intra-osseous tumor growth. *Molecular Cancer Research*. 6(3):446-457, 2008. (¹*Corresponding author*). [Journal impact factor: 4.4; Cited: 21]
25. Aneja R., Miyagi, T., Karna, P., Ezell, T., Shukla, D., Gupta, M. V., Yates, C., **Chinni, S.R.**, Zhau, H., Chung, L.W.K. and Joshi, HC. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. *European Journal of Cancer*. 46(9):1668-78., 2010. [Data analysis, intellectual input, and addressing some of the reviewer queries]. [Journal impact factor: 4.9; Cited: 5]
26. Parajuli P, Joshee, N, **Chinni, S.R.**, Rimando, A.M., Mittal, S, Yadav, AK. Delayed growth of glioma by Scutellaria flavinoids involves inhibition of Akt, GSK-3 and NF- κ B signaling. *J. Neuro-oncol*, 101(1):15-24, 2010. [Study design, data analysis, intellectual input, manuscript writing for select sections, addressing some of the reviewer queries]. [Journal impact factor: 2.9; Cited: 1]
27. [§]Cai, J., #Kandagatla, P., *Singareddy, R., [§]Kropinski, A., Sheng, S., Cher, M.L., and **Chinni, S.R.** Androgens Induce Functional CXCR4 via ERG Factor Expression in TMPRSS2-ERG Fusion Positive Prostate Cancer Cells. *Translational Oncology*. 3(3):195-2003, 2010. ([§]*Research Assistant #Undergraduate student, *Post-doctoral fellow in Dr. Chinni's lab*).
28. *Conley-LaComb, M, Saliganan A, #Kandagatla P, Chen, YQ, Cher ML, **Chinni S.R.** PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. *Mol Cancer*. 12(1):85, 2013. (**Post-doctoral fellow in Dr. Chinni's lab #Undergraduate student in Dr. Chinni's lab*).
29. *Singareddy R., *Coney-LaComb M, [§]Semaan L, #St. John J, #Powell K, Smith D,

Heilbrun LK, Shi D, Sakr W, Cher ML, **Chinni, S.R.** Transcriptional regulation of CXCR4 in prostate tumor cells: Significance of TMPRSS2-ERG fusions. *Molecular Cancer Research* 11(11):1349-61, 2013. (*§Research Assistant #Master`s student, #Graduate student in Dr. Chinni`s lab *Post-doctoral fellow in Dr. Chinni`s lab*).

30. Wong D, #Kandagatla P, Korz W, **Chinni S. R.** Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. *BMC Urology*. 2014 Jan 28;14(1):12. doi: 10.1186/1471-2490-14-12 (*#Undergraduate student in Dr. Chinni`s lab*).

31. *Singareddy R., *Coney-LaComb M, \$Semaan L, Li Y, #Sukhadeep B, Cher ML, **Chinni, S.R.** CXCL12/CXCR4 transactivates HER2 and Src through small GTP proteins in lipid raft membrane microdomains and promotes bone tumor growth through initial establishment in bone microenvironment (In preparation). (*§Research Assistant, #Undergraduate student, *Post-doctoral fellow in Dr. Chinni`s lab*).

32. Powell IJ, Dyson G, **Chinni S.R.**, Bollig-Fischer A. Considering race and the potential for ERG expression as a biomarker for prostate cancer. *Personalized Medicine*. 11(4):409-412. 2014.

33. #Powell K, \$Semaan L,*Conley-LaComb M, \$Li Y, M Maddipati K, Ross I, Cher ML, and **Chinni S.R.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. *Clinical Cancer Research*. 2015 Jun 1;21(11):2569-79. (*§Research Assistant, #Graduate student, *Post-doctoral fellow in Dr. Chinni`s lab*).

34. Sakao K, Vyas AR, **Chinni S.R.**, Amajad AI, Parikh R, Singh SV. CXCR4 is a novel target of cancer chemopreventive isothiocyanates in prostate cancer cells. *Cancer Prev Res*. 2015 May 8(5):365-74.

REVIEW ARTICLES:

Bonfil, R. D., **Chinni, S. R.**, Fridman, R., Kim, H-R., Cher, M. L. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. *Urologic Oncology*. 25:407- 411, 2007. [Contributed one figure in this review].
[Journal impact factor: 3.1; Cited: 16]

#St. John, J, #Powell, K, *Conley-LaComb, M, and **Chinni, S.R.** *TMPRSS2-ERG* fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. *Journal of Cancer Science and Therapy*. 4(4):94-101, 2012. (*#Graduate student, *Post-doctoral fellow in Dr. Chinni`s lab*)

PUBLISHED ABSTRACTS:

1. **Chinni, SR.**, Falchatto, R. A., Shabanowitz, J., Hunt, D.F., Gercel-Taylor, C. and Taylor, D. D Identification of ovarian carcinoma associated antigens by patients' immune responses. Proceedings of the American association of cancer research. Vol. 37, April 1996.
2. **Chinni, SR.**, Conner, G.E. and Taylor, D.D. Cathepsin D elicits immune response in ovarian cancer patients. ASBMB/ASIP/AAI joint meeting. June 1996.
3. **Chinni, SR** and Shisheva, A. Free and Rab-bound soluble forms of GDIs in intact cells. VII International symposium on Insulin Receptors & Insulin Action, Jerusalem, Israel, May 1998.
4. **Chinni, SR**, and Shisheva, A. Arrest of endosome acidification by Bafilomycin A1 mimics insulin action on GLUT4 translocation in 3T3-L1 adipocytes. VII International symposium on Insulin Receptors & Insulin Action, Jerusalem, Israel, May 1998.
5. **Chinni, SR** and Shisheva, A. Discriminating between Rab4 and Rab5 interactions with GDI-2 mutants. International Motor City Diabetes Symposium, Detroit, MI, October 16-17, 1998.
6. **Chinni, SR** and Shisheva, A. Mapping GDI-2 functional amino acids involved in interactions with Rab4 and Rab9. 38th Annual meeting of the American Society for Cell Biology, San Francisco, USA, December 12-16, 1998.
7. **Chinni, SR**, and Shisheva, A. Functional analysis of GDI-2: Modulations of its Rab interactions by *in vivo* and *in vitro* structural modifications. Annual meeting of American Diabetes Association. San Diego, CA, April 1999.
8. **Chinni, SR**, Li Yei and Sarkar, F.H. Molecular effects of Indole-3-Carbinol on PC3 prostate cancer cells. 9th Annual AICR conference on Nutrition and Cancer Prevention: New Insights into the role of phytochemicals. Washington, DC, September 2 and 3, 1999.
9. **Chinni, SR**, Koppolu, P.K and Sarkar, F.H. Molecular mechanism(s) of indole-3-carbinol induced G1 arrest in prostate cancer cells. 2000 American Association of Cancer Research. San Francisco, CA, April 1 - 5, 2000.
10. **Chinni SR**, Gohde JC, Sarkar FH. Inhibition of AKT Survival Pathway is Responsible for Indole-3-Carbinol Induced Apoptosis in Prostate Cancer Cells. Proc Amer Assoc Cancer Res 42:705A, 2001.
11. **Chinni SR**, Deng X, Dong Z, Bhagat S, Bonfil RD, Cher ML. The Role of SDF-1 α /CXCR4/MMP-9 in Prostate Cancer Bone Metastasis. J Urol 169:354A, 2003.
12. Deng X, Bhagat S, Filetti LC, Dong Z, Mullins C, **Chinni SR**, R Bonfil RD, Cher ML. Genetic Modification of Human Bone with TIMP-1 And -2 Adenoviral Vectors to

Create a Hostile Microenvironment for Prostate Cancer Metastasis. Proc Amer Assoc Cancer Res 44:3337A, 2003.

13. Dong Z, Bhagat S, Filetti LC, Bonfil RD, **Chinni SR**, Deng X, Fridman R, Cher ML. Matrix Metalloproteinase-9 Activity in Human Bone Microenvironment Colonized by Prostate Cancer Cells. Proc Amer Assoc Cancer Res 44:3269A, 2003.
14. **Chinni, SR**, Deng, X, Dong, Z, Nemeth, JA, Bhagat, S and Cher, ML. The role of SDF-1 α /CXCR4/MMP-9 in prostate cancer bone metastasis. Metastatic Research Society Meeting, Chicago, September 2002.
15. **Chinni SR**, Deng X, Dong Z, Nemeth JA Bhagat S, Cher ML. The role of SDF1 α /CXCR4/MMP-9 in prostate cancer bone metastasis. *Clin Exp Met* 19 (Suppl 1): O-05, 2002.
16. Dong Z, Bonfil D, **Chinni SR**, Trindade JC, Bhagat S, Sivalogan S, Fridman R, and Cher M. Osteoclast recruitment, MMP-9 expression and tissue MMP-9 proteolytic activity in prostate cancer bone metastasis. The Program of IVth International Conference on Cancer-Induced Bone Diseases. December 2003; p44.
17. **Chinni SR**, Dong Z, Sivalogan, S, Trindade Filho JC, Bhagat S, Bonfil R and Cher ML. CXCR4 and MMP-9 in prostate cancer bone metastasis. The IVth international conference on cancer-induced bone diseases. December 2003; p25.
18. Dong Z, Bonfil D, **Chinni SR**, Trindade JC, Bhagat S, Sivalogan S, Fridman R, and Cher M. Enhanced osteoclast motility due to overexpression of MMP-9 induced by prostate cancer cells. *Proceedings of 95th Annual Conference*, American Association for Cancer Research. CD-ROM, 2004.
19. **Chinni, SR**, Sivalogan S, Dong Z, Trindade Filho JC, Bhagat S; Bonfil RD and Cher, ML. Akt activation and MMP-9 secretion in prostate cancer bone interaction. *Proceedings of 95th Annual Conference*, American Association for Cancer Research. CD-ROM, 2004.
20. **Chinni, SR**, Sivalogan S, Dong Z, Trindade Filho JC, Bonfil RD and Cher, ML. CXCL12/CXCR4 signaling induces Akt activation and MMP-9 expression in prostate cancer cells. Eleventh Annual Prostate Cancer Foundation Scientific Retreat, Lake Tahoe, NV. October 21-24, 2004.
21. **Chinni, SR**, Sivalogan S, Dong Z, Trindade Filho JC, Bonfil RD and Cher, ML. CXCL12 and CXCR4 interaction in prostate cancer induces akt signaling, mmp-9 expression, motility and invasion 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA. CD-ROM, 2005.
22. **Chinni, SR**, Sivalogan S, Dong Z, Trindade Filho JC, Bonfil RD and Cher, ML. The bone microenvironment induces CXCL12/CXCR4 signaling, Akt activation, and MMP-9 expression in prostate cancer cells. IV symposium on skeletal complications of malignancy, NIH, Bethesda, MD. April 28-30, 2005.

23. **Chinni, SR**, Sivalogan S, Dong Z, Trindade Filho JC, Bonfil RD and Cher, ML. CXCL12 chemokine-CXCR4 receptor interaction in prostate cancer induces akt signaling, mmp-9 expression, motility and invasion. American Urological Association annual meeting, San Antonio, TX. May 21-26, 2005.
24. Bonfil RD, Sabbota A, Nabha S, Dong Z, Trindade Filho JC, **Chinni, SR**, Zhang W-M, Bernardo M, Brown S, Chang M, Mobashery S, Cher, ML and Fridman R. Inhibition of human prostate cancer growth and osteolysis in a bone metastasis model by a mechanism-based specific gelatinase inhibitor (SB-3CT). 96th Annual Meeting of American Association for Cancer Research. Anaheim, CA. CD-ROM, 2005.
25. Trindade Filho JC, Bonfil RD, Dong Z, **Chinni, SR**, Nabha S, Zhang W-M, Fridman R and Cher, ML. Overexpression of membrane type-1 matrix metalloproteinase in LNCaP prostate carcinoma cells enhances tumor growth and matrix degradation in a bone metastasis model. American Urological Association annual meeting, San Antonio, TX. May 21-26, 2005.
26. **Chinni, SR**, Sivalogan, S, Yamamoto, H, Sabbota, A, Dong, Z, Weisner, C, Nabha, S, Bonfil RD and Cher, ML. CXCL12 induced HER2 trans-activation in lipid rafts confers MMP-9 production and chemoinvasion in PC cells. 6th Annual Symposium Michigan Prostate Research Colloquium Basic and Clinical Advances in Prostate Cancer Research. University of Michigan Medical School, Towsley Center, May 6, 2006.
27. **Chinni, SR**, Yamamoto, H, Dong, Z, Sabbota, A, Nabha, S, Bonfil RD and Cher, ML. CXCL12/CXCR4 trans-activates HER2 in lipid rafts of PC cells and promotes intraosseous tumor growth. American Association of Cancer Research annual meeting 2007. April 14-18, 2007.
28. Dong, Z, Bonfil, RD, Yamamoto HA, **Chinni, SR**, Saliganan A, Meng H, Nabha SM, Sabbota A, Wiesner C, Cher ML. Silencing urokinase-type plasminogen activator in prostate cancer cells reduces their intraosseous proliferation and bone degradation. American Association of Cancer Research annual meeting 2007. April 14-18, 2007.
29. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota, A., Osenkowski, P., Nabha S., Yamamoto, H., **Chinni, SR**, Zhao H, Mobashery S, Vessella R, Fridman R and Cher, ML. Prostate Cancer-Associated Membrane Type-1 Matrix Metalloproteinase: a Pivotal Role in Bone Metastasis. American Urological Association annual meeting, Anaheim, CA. May 19-24, 2007.
30. **Chinni, SR**, Yamamoto H, Dong Z, Sabbota A, Nabha S, Bonfil RD and Cher, ML. CXCL12/CXCR4 trans-activation of HER2 in lipid rafts of prostate cancer cell membranes promotes bone metastasis. American Urological Association annual meeting, Anaheim, CA. May 19-24, 2007.
31. **Chinni, SR**, Sivalogan, S, Dong, Z, Bonfil, RD and Cher, ML. CXCL12/CXCR4

Transactivates HER2 in lipid rafts, Induces AKT activation, MMP-9 Expression in Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone. Innovative Minds in Prostate Cancer Today (IMPACT) meeting. Atlanta, GA. September 5-8, 2007.

32. **Chinni, SR**, Sheng S and Cai J. Androgen induced ERG transcription factor regulates CXCR4 gene expression and function in prostate cancer cells. Joint Metastasis Research Society-AACR conference. Vancouver, British Columbia, Canada. August 3-7, 2008.
33. **Chinni, SR**, Sheng S and Cai J. Androgens regulate CXCR4 expression and function in TMPRSS2-ERG translocation positive prostate cancer cells. Advances in Prostate Cancer Research. San Diego, CA. January 21-24, 2009.
34. **Chinni, SR**, Cai J, Sheng S and Kropinski A. CXCR4 is a target for androgen activated TMPRSS2-ERG fusions in prostate cancer cells. The 16th annual scientific retreat of Prostate Cancer Foundation. Lake Tahoe, NV. September 23-26 2009.
35. **Chinni, SR**, Kandagatla P, Wong D and Korz W. CXCR4 antagonist, CTCE-9908 inhibits PC-3 cell invasiveness and metastasis. American Association of Cancer Research annual meeting 2010. Washington, DC. April 17-21, 2010.
36. **Chinni, SR**, Singareddy R, St. John J and Cai J. Role of ERG and CXCR4 in prostate cancer progression. Innovative Minds in Prostate Cancer Today (IMPACT). Orlando, Florida. March 9-12, 2011.
37. Singareddy R, St. John J and **Chinni, SR**. Molecular characterization of ERG mediated CXCR4 transcriptional regulation. American Association of Cancer Research Annual meeting 2011, Orlando, Florida. April 2-6, 2011.
38. Conley-LaComb, M, Chen YQ., Kim HR, Cher ML, **Chinni, SR**. Regulation of expression of CXCL12 and its receptors, CXCR4 and CXCR7, by PTEN in prostate cancer. Annual Retreat of the Proteases and Cancer Program. Wayne State University, Detroit, MI. December 1, 2011.
39. Conley-LaComb, M, Chen YQ, HR Kim, Cher ML and **Chinni SR**. Regulation of expression of CXCL12 and its receptors, CXCR4 and CXCR7, by PTEN in prostate cancer. An AACR special conference on Advances in Prostate Cancer Research. Orlando FL. February 6-9, 2012.
40. Conley-LaComb M, Saliganan, A, Chen YQ, HR Kim, Cher ML and **Chinni SR**. PTEN loss mediated Akt activation promotes prostate tumor growth via CXCL12/CXCR4 signaling. Frontiers of Tumor and Microenvironment Symposium. Wayne State University, Detroit, MI. December 12, 2012.
41. Powell K, Semaan L, Conley-LaComb K, Singareddy R, and **Chinni S.R**. ERG regulates androgen biosynthetic enzyme gene expression in prostate cancer. The 2nd Annual Cancer Biology Research Symposium. Detroit, Michigan. May 10, 2012.

42. Powell K, Semaan L, Maddipati K, and **Chinni S.R.** ERG regulates androgen biosynthetic enzyme gene expression in prostate cancer. The 16th Annual Wayne State University Graduate Student Research Day. Detroit, MI. September 27, 2012.
43. Powell K, Semaan L, Maddipati K, and **Chinni S.R.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. Frontiers of Tumor and Microenvironment Symposium. Detroit, MI. December 12, 2012.
44. Powell K, Semaan L, Maddipati K, and **Chinni S.R.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. The 3rd Annual Cancer Biology Research Symposium. Detroit, MI. February 28, 2013.
45. Conley-LaComb, Saliganan, A, Chen YQ, HR Kim, Cher ML and **Chinni SR.** PTEN loss mediated Akt activation promotes prostate tumor growth via CXCL12/CXCR4 signaling. American Association for Cancer Research Annual meeting. Washington, D.C. April 6-10, 2013.
46. Conley-LaComb M, Semaan L, Sukhdeep B, and **Chinni SR.** Inhibition of CXCR4 Reduces Initial Prostate Tumor Growth in the Bone. Tumor and Microenvironment Retreat. Wayne State University, Detroit, MI. December 4, 2013.
47. Conley-LaComb M, Saliganan A, Chen YQ, Cher ML, **Chinni SR.** PTEN loss-mediated Akt activation promotes prostate tumor growth via CXCL12/CXCR4 signaling. AACR Annual Meeting 2013, Washington, D.C. April 6-10, 2013.
48. Powell K, Semaan L, Maddipati K, and **Chinni SR.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. The 3rd Annual Cancer Biology Research Symposium. Detroit, MI. February 28, 2013.
49. Powell K, Semaan L, Maddipati K, and **Chinni S.R.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. 4th Annual Cancer Biology Research Symposium, Wayne State. University, Detroit, MI. February 2014.
50. Powell K, Semaan L, Maddipati K, Conley-LaComb K, Li Y, Cher M, and **Chinni S.R.** ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression. 105th Annual Meeting of the American Association of Cancer Research, San Diego, CA. April, 2014.
51. Ross I, Powell K, Semaan L, Conley-LaComb M, Li Y, **Chinni S.R.** TMPRSS2-ERG fusions regulate intratumoral androgen production in castrate resistant prostate cancer progression. Michigan Urological Society Meeting. Detroit, MI, June 2014.
52. Powell K, Semaan L, Maddipati K, Conley-LaComb K, Li Y, Cher M, and **Chinni S.R.** TMPRSS2-ERG regulation of intratumoral androgen synthesis and castration-resistant prostate cancer progression. Lipids@Wayne Inaugural Symposium, Wayne State University, Detroit, MI. June 2014.

53. Sbrissa D, Semaan L, Li Y, Shisheva A and **Chinni S.R.** Phosphatidylinositol 4-kinase type III α (PI4KA) and CXCR4 crosstalk in prostate cancer cells. Karmanos Cancer Institute and Wayne State University Tumor Biology and Microenvironment program annual retreat. Detroit, MI, December 12, 2014.
54. Sbrissa, D., Semaan, L., Yanfeng L., Shisheva, A. and **Chinni, S.R.** "Phosphatidylinositol 4-kinase Type III α (PI4KA) expression in prostate cancer cells". Poster presentation at the Annual American Association for Cancer Research Meeting at the Pennsylvania Convention Center, Philadelphia, Pennsylvania. April 18-22, 2015.
55. Smith, D., Sbrissa, D., Semaan, L., Yanfeng L., Shisheva, A. and **Chinni, S.R.** "Phosphatidylinositol 4-kinase Type III α (PI4KA) expression in prostate cancer cells". Presentation at the 2015 Cancer Biology Summer Undergraduate Research Fellowship Program poster session at Wayne State University School of Medicine, in Detroit, Michigan. August 7, 2015.
56. Sbrissa, D., Semaan, L., Yanfeng L., Shisheva, A. and **Chinni, S.R.** "Phosphatidylinositol 4-kinase type III α (pi4ka) and cxcr4 crosstalk in prostate cancer cells". Poster presentation at the 4th Annual Tumor Biology and Microenvironment Program Meeting at Wayne State University School of Medicine, in Detroit, Michigan. November 18th, 2015.

INVITED LECTURES/PRESENTATIONS:

Invited/refereed presentations at international/national meetings:

1. The role of SDF-1 α /CXCR4/MMP-9 in prostate cancer bone metastasis. Metastatic Research Society Meeting, Chicago, September 2002.
2. CXCR4 and MMP-9 in prostate cancer bone metastasis. The IVth International conference on cancer induced bone diseases. San Antonio, TX. December 2003.
3. The role of ERG and CXCR4 in Prostate Cancer Metastasis. The 16th annual scientific retreat of Prostate Cancer Foundation. Lake Tahoe, NV. September 2009.
4. Role of ERG and CXCR4 in Prostate Cancer Progression. Innovative Minds in Prostate Cancer Today (IMPACT). Orlando, FL. March 2011.
5. The role of ERG and CXCR4 in Prostate Cancer Bone Metastasis. 7th Annual National Symposium on Prostate Cancer. Center for Cancer Research and Therapeutic Development (CCRTD), Clark Atlanta University, Atlanta. May 2011.

Invited/refereed presentations at local/regional meetings:

1. Role of CXCR4 and MMP-9 in prostate cancer bone metastasis. Plenary lecture. Vth

- Annual Michigan Prostate Research Colloquium on basic and clinical advances of prostate cancer. April 23, 2005.
2. Prostate cancer bone metastasis: molecular and cellular mediators. 5th Annual Prostate Cancer Symposium. Charles H. Wright Museum of African American History. September 19, 2015

Invited Seminars and Grand Rounds:

1. Molecular action of Indole-3-Carbinol on prostate adenocarcinoma cells. Novartis Pharma, Summit, NJ. May 5th, 2000.
2. Role of GDI in intracellular vesicular traffic and growth factor signaling. Department of Pathology, Wayne State University, Detroit, MI. July 2000.
3. Indole-3-Carbinol modulates cell survival proteins in prostate cancer cells. Bio-Rad, Hercules, CA. April, 2001.
4. The role of SDF-1 α /CXCR4/MMP-9 in prostate cancer bone metastasis. Protease Group Meeting, Karmanos Cancer Institute, Wayne State University, Detroit. December 2002.
5. Role of CXCR4 and MMP-9 in prostate cancer bone metastasis. Pathology lecture series, Wayne State University, Detroit, MI. May 31, 2006.
6. Role of CXCR4 in prostate cancer metastasis. Cell signaling group meeting, Karmanos Cancer Institute, Wayne State University, Detroit, MI. March 21st, 2007.
7. The role of ERG and CXCR4 in Prostate Cancer Metastasis. Prostate Cancer Working Group meeting, Wayne State University, Detroit, MI. October 2nd, 2009.
8. The role of ERG and CXCR4 in Prostate Cancer Metastasis. Protease group meeting, Wayne State University, Detroit, MI. October 7th, 2009.
9. Prostate Cancer and Role of Chemokines in Metastasis. Urology Grand Rounds, Wayne State University, Detroit, MI. October 30th, 2009.
10. Novel ERG regulation of CXCR4 expression in Prostate Cancer Metastasis. KCI 2010 Research Retreat, Wayne State University, Detroit, MI. June 25th, 2010.
11. Role of ERG and CXCR4 in Prostate Cancer Progression. Prostate Cancer working group. Wayne State University, Detroit, MI. March 2011.
12. CXCR4 expression and signaling in lipid raft microdomains in prostate cancer cells. Department of Pathology, Wayne State University. February 2012.
13. CXCL12/CXCR4 signaling in prostate cancer metastasis. Tumor and Microenvironment Program meeting, Karmanos Cancer Institute. September 2012.

14. TMPRSS2-ERG Fusions Regulate Intratumoral Androgen Production in Castrate Resistant Prostate Cancer Progression. Karmanos Cancer Institute Research Retreat. November 22, 2013.
15. Chemokines and androgens in prostate cancer progression. Tumor and Microenvironment Program meeting, Karmanos Cancer Institute. December 2, 2013.
16. ERG, Chemokine signaling and Androgen biosynthesis in prostate cancer. Great Lakes Spore Symposium, KCI, December, 19, 2014.